LONDON: Oakley Capital Investments Limited announced that Oakley Capital IV (Fund IV) has agreed to acquire WindStar Medical GmbH from ProSiebenSat.1 majority-owned NuCom Group.
WindStar Medical is Germany’s leading over-the-counter (OTC) consumer healthcare company. The platform, which is expected to generate over €120 million in revenues this year, designs, develops and commercialises branded consumer health and private label products, with a track record of establishing best-in-class medical formulations and brands.
The Consumer Brands segment of WindStar Medical offers a wide range of premium high-growth branded products in Germany, including SOS (wound care / disinfectants), Zirkulin (gastro-intestinal care), GreenDoc (mental wellbeing) and EyeMedica (eye health).
WindStar Medical is also a provider of Private Label products to the leading German drug stores and supermarkets, whilst also developing an international distribution footprint through existing and new partners.
WindStar Medical benefits from the long-term structural growth of Germany’s consumer health market. This growth is being driven both by demographic trends, such as an ageing population, and a shift in consumer preferences driven by factors such as increased awareness of physical and mental wellbeing and willingness to prevent illness.
Through its investment, Oakley will support the company’s management team as they continue to drive revenue growth, product innovation, digitalisation, as well as identifying opportunities to scale the business through accretive acquisitions.
The investment in WindStar Medical builds on Oakley’s successful track record of investing in leading consumer platforms in the DACH region, including Verivox, Parship Elite and more recently Wishcard Technologies and 7NXT / Gymondo. The business displays the typical Oakley deal characteristics, as it has an asset-light business model, industry-leading operational capabilities, and an attractive growth profile.
OCI’s indirect contribution through its interest in Fund IV will be up to c.£43 million, dependent on the capital structure at completion, and the transaction is expected to be completed by the end of the year.
Peter Dubens, Managing Partner of Oakley Capital, commented: “WindStar Medical is a unique OTC platform in a highly attractive space that Oakley is excited to be investing in, having closely followed both the development of the business and management over recent years. We look forward to working together with the team and utilising our broad expertise in digitalisation, go-to-market and M&A to help WindStar Medical accelerate its growth trajectory in Germany and international markets.”
Oakley Capital Investments Limited (OCI) is a Specialist Fund Segment (SFS) traded investment vehicle that aims to provide shareholders with consistent long-term capital growth in excess of the FTSE All-Share Index by providing liquid access to private equity returns through investment in the Oakley Funds.